However, the bulk of myeloma-related work using BiTEs has been based on recombinant antibodies to two different epitopes designed to cross-link the CD3ζ chains on the surface of tumor-specific T-cells and the targeted myeloma-BCMA. The gene discussed is TNFRSF17; the disease is neoplasm.